PALO ALTO, Calif.--(BUSINESS WIRE)--KaloBios Pharmaceuticals, Inc. a privately held biopharmaceutical company, today announced the signing of an agreement with Novartis to non-exclusively license KaloBios’ proprietary Humaneering™ technology for use at Novartis’ research sites to develop human antibodies for therapeutic indications. This is the first such non-exclusive technology transfer that KaloBios has offered for its Humaneering™ platform. As part of the transition plan, KaloBios has agreed to Humaneer™ three additional antibodies for Novartis in addition to the three that have been successfully completed as part of a pilot R&D relationship.
